Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistinė fibrozė - kiti kvėpavimo sistemos produktai - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - imunosupresantai - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - imuninės serumai ir imunoglobulinai, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

orpha-devel handels und vertriebs gmbh - treprostinilis - infuzinis tirpalas - 2,5 mg/ml - treprostinil

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

orpha-devel handels und vertriebs gmbh - treprostinilis - infuzinis tirpalas - 5 mg/ml - treprostinil

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

orpha-devel handels und vertriebs gmbh - treprostinilis - infuzinis tirpalas - 10 mg/ml - treprostinil

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - virškinimo trakto stromos navikai - antinavikiniai vaistai - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antinavikiniai vaistai - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - daugybinė mieloma - antinavikiniai vaistai - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

amryt pharmaceuticals dac - octreotide acetate - akromegalija - hipofizės ir hipotalaminiai hormonai ir analogai - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.